Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2008 Jan 23;2008(1):CD005312.
doi: 10.1002/14651858.CD005312.pub2.

Hawthorn extract for treating chronic heart failure

M H Pittler, R Guo, E Ernst
Meta-Analysis

Hawthorn extract for treating chronic heart failure

M H Pittler et al. Cochrane Database Syst Rev. .

Abstract

Background: Hawthorn extract is advocated as an oral treatment option for chronic heart failure. Also, the German Commission E approved the use of extracts of hawthorn leaf with flower in patients suffering from heart failure graded stage II according to the New York Heart Association.

Objectives: To assess the benefits and harms as reported in double-blind randomised clinical trials of hawthorn extract compared with placebo for treating patients with chronic heart failure.

Search strategy: We searched CENTRAL on The Cochrane Library (issue 2, 2006), MEDLINE (1951 to June 2006), EMBASE (1974 to June 2006), CINAHL (1982 to June 2006) and AMED (1985 to June 2006). Experts and manufacturers were contacted. Language restrictions were not imposed.

Selection criteria: To be included, studies were required to state that they were randomised, double-blind, and placebo controlled, and used hawthorn leaf and flower extract monopreparations.

Data collection and analysis: Two reviewers independently performed the selection of studies, data extraction, and assessment of methodological quality. Data were entered into RevMan 4.2 software. Results from continuous data were reported as weighted mean difference (WMD) with 95% confidence interval (CI). Where data were suitable for combining, pooled results were calculated.

Main results: Fourteen trials met all inclusion criteria and were included in this review. In most of the studies, hawthorn was used as an adjunct to conventional treatment. Ten trials including 855 patients with chronic heart failure (New York Heart Association classes I to III) provided data that were suitable for meta-analysis. For the physiologic outcome of maximal workload, treatment with hawthorn extract was more beneficial than placebo (WMD (Watt) 5.35, 95% CI 0.71 to 10.00, P < 0.02, n = 380). Exercise tolerance were significantly increased by hawthorn extract (WMD (Watt x min) 122.76, 95% CI 32.74 to 212.78, n = 98). The pressure-heart rate product, an index of cardiac oxygen consumption, also showed a beneficial decrease with hawthorn treatment (WMD (mmHg/min) -19.22, 95% CI -30.46 to -7.98, n = 264). Symptoms such as shortness of breath and fatigue improved significantly with hawthorn treatment as compared with placebo (WMD -5.47, 95% CI -8.68 to -2.26, n = 239). No data on relevant mortality and morbidity such as cardiac events were reported, apart from one trial, which reported deaths (three in active, one in control) without providing further details. Reported adverse events were infrequent, mild, and transient; they included nausea, dizziness, and cardiac and gastrointestinal complaints.

Authors' conclusions: These results suggest that there is a significant benefit in symptom control and physiologic outcomes from hawthorn extract as an adjunctive treatment for chronic heart failure.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Funnel plot to examine publication bias
1.1
1.1. Analysis
Comparison 1 Hawthorn extract versus placebo, Outcome 1 Maximum work load.
1.2
1.2. Analysis
Comparison 1 Hawthorn extract versus placebo, Outcome 2 Exercise tolerance (Watt min).
1.3
1.3. Analysis
Comparison 1 Hawthorn extract versus placebo, Outcome 3 Pressure‐heart rate product.
1.4
1.4. Analysis
Comparison 1 Hawthorn extract versus placebo, Outcome 4 Symptom scores according to v Zerssen.
1.5
1.5. Analysis
Comparison 1 Hawthorn extract versus placebo, Outcome 5 6‐min walk test.
1.6
1.6. Analysis
Comparison 1 Hawthorn extract versus placebo, Outcome 6 LVEF%.
2.1
2.1. Analysis
Comparison 2 Sensitivity test, Outcome 1 Maximal workload (Watt) ‐ with additional medication.
2.2
2.2. Analysis
Comparison 2 Sensitivity test, Outcome 2 Maximal workload (Watt) ‐ use of additional medication unclear.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Aaronson 2004 {published data only}
    1. Aaronson K in Liu P, Konstam MA, Force T. Highlights of the 2004 scientific sessions of the Heart Failure Society of America, Toronto, Canada, September 12 to 15, 2004. Journal of the American College of Cardiology 2005;45:617‐25. - PubMed
    1. Lalukota K, Cleland JGF, Ingle L, Clark AL, Coletta AP. Clinical trials update from the Heart Failure Society of America: EMOTE, HERB‐CHF, BEST genetic sub‐study and RHYTHM‐ICD. European Journal of Heart Failure 2004;6:953‐5. - PubMed
Alexander 1995 {unpublished data only}
    1. Alexander HA. Clinical effects of Crataegus extract LI132 for treating heart insufficiency stage 2 New York Heart Association. A randomised placebo‐controlled double‐blind study with n=73 patients [Klinische Wirkung des Crataegus‐Extraktes Li 132 bei der Therapie der Herzinsuffizienz im Stadium II der New York Heart Association. Eine randomisierte, placebokontrollierte Doppelblindstudie an n = 73 Patienten]. Dissertation (Dr. med), Charité University Medical Centre, Berlin, Germany 1995.
Bödigheimer 1994 {published and unpublished data}
    1. Bödigheimer K, Chase D. Effectiveness of hawthorn extract at a dosage of 3 x 100 mg per day. Multicentre double‐blind trial with 85 NYHA stage II heart failure patients. Munchener Medizinische Wochenschrift 1994;136(Suppl 1):S7‐S11. [MEDLINE: ; 0341‐3098]
Eichstädt 2001 {published and unpublished data}
    1. Eichstädt H, Störk T, Möckel M, et al. Effectiveness of and tolerance to Crataegus extract WS1442 in patients with heart insufficiency and reduced leftventricular function [Wirksamkeit und Verträglichkeit von Crataegus‐Extrakt WS®1442 bei herzinsuffizienten Patienten mit eingeschränkter linksventrikulärer Funktion]. Perfusion 2001;14:212‐7.
Förster 1994 {published data only}
    1. Förster A, Förster K, Buhring M, Wolfstadter HD. Crataegus for moderately reduced left ventricular ejection fraction. Ergospirometric monitoring study with 72 patients in a double‐blind comparison with placebo. Munchener Medizinische Wochenschrift 1994;136(Suppl 1):S21‐S26. [MEDLINE: ; 0341‐3098]
Hanak 1983 {published and unpublished data}
    1. Hanak T, Bruckel MH. Treatment of mild stable forms of angina pectoris with a standardized Crataegus extract [Behandlung von leichten stabilen formen der angina pectoris mit crataegutt novo]. Therapiewoche 1983;33:4331‐3.
Iwamoto 1981 {published data only}
    1. Iwamoto M, Ishizaki T, Sato T. The clinical effect of Crataegutt in heart disease of ischemic or hypertensive origin. A multicenter double‐blind study [Klinische Wirkung von Crataegutt bei Herzerkrankungen ischämischer und/oder hypertensiver Genese. Eine multizentrische Doppelblindstudie]. Planta Medica 1981;42:1‐16. - PubMed
Leuchtgens 1993 {published and unpublished data}
    1. Leuchtgens H. The Crataegus special extract WS 1442 in patients with cardiac insufficiency NYHA II. A placebo‐controlled double‐blind study [Crateagus‐spezialextrakt ws 1442 bei herzinsuffizienz nyha ii. Eine plazebokontrollierte randomisierte doppelblindstudie]. Fortschritte der Medizin 1993;111(20‐21):36‐8. [MEDLINE: ; 0015‐8178] - PubMed
O'Connolly 1987 {published and unpublished data}
    1. O'Connolly M, Bernhoft G, Bartsch G. Treatment of cardiac symptoms in old patients with multiple pathology. Therapiewoche 1987;37(38):3587‐3600. [MEDLINE: ; 0040‐5973]
O'Conolly 1986 {published and unpublished data}
    1. O'Conolly M, Jansen W, Bernhöft G, Bartsch G. Treatment of decreasing cardiac performance Therapy using standardized crataegus extract in advanced age [Behandlung der nachlassenden Herzleistung. Therapie mit standardisiertem Crataegus‐Extrakt im hoheren Lebensalter]. Fortschritte der Medizin 1986;104(42):805‐8. [MEDLINE: ; 0015‐8178] - PubMed
Schmidt 1994 {published data only}
    1. Schmidt U, Kuhn U, Ploch M, Hübner W‐D. Efficacy of the Hawthorn (Crataegus) preparation LI 132 in 78 patients with chronic congestive heart failure defined as NYHA functional class II. Phytomedicine 1994;1:17‐24. - PubMed
    1. Schmidt U, Kuhn U, Ploch M, Hübner W‐D. Efficacy of the hawthorn extract LI132 (600 mg/d) during eight weeks treatment. Placebo controlled double blind trial with 78 NYHA stage II heart failure patients [Wirksamkeit des extraktes li 132 (600 mg/tag) bei achtwochiger therapie. Placebokontrollierte doppelblindstudie mit weissdorn an 78 herzinsuffizienten patienten im stadium ii nach nyha.]. Munchener Medizinische Wochenschrift 1994;136(Suppl 1):S13‐S19.
Tauchert 2002 (HD) {published and unpublished data}
    1. Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class‐III heart failure. American Heart Journal 2002;143:910‐5. - PubMed
Tauchert 2002 (LD) {published and unpublished data}
    1. Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class‐III heart failure. American Heart Journal 2002;143:910‐5. - PubMed
Weikl 1996 {published and unpublished data}
    1. Weikl A, Assmus KD, Neukum S, A, Schmitz J, Zapfe G, Noh HS, et al. Crataegus Special Extract WS 1442 Assessment of objective effectiveness in patients with heart failure NYHA II. Fortschritte der Medizin 1996;114(24):291‐6. [MEDLINE: ; 0015‐8178] - PubMed
Zapfe 2001 {published and unpublished data}
    1. Zapfe JG. Clinical efficacy of crataegus extract WS 1442 in congestive heart failure NYHA class II. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology 2001;8(4):262‐6. [MEDLINE: ; 0944‐7113] - PubMed

References to studies excluded from this review

Czerny 1996 {published data only}
    1. Czerny B, Samochowiec J. Clinical investigation of a garlic‐lecithin preparation [Klinische Untersuchungen mit einem Knoblauch‐Lezithin‐Präparat]. Ärztezeitschrift Naturheilverfahren 1996;37:126‐36.
Degenring 2003 {published data only}
    1. Degenring FH, Suter A, Weber M, Saller R. A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 2003;10:363‐9. - PubMed
Eichstädt 1989 {published data only}
    1. Eichstädt H, Bäder M, Danne O. Crataegus extract helps patients with heart insufficiency stage 2 NYHA [Crataegus‐Extrakt hilft dem Patienten mit NYHA II‐Herzinsuffizienz.]. Therapiewoche 1989;39:3288‐96.
Eiff 1994 {published data only}
    1. Eiff M, Brunner H, Haigeli A, Kreuter U, Martina B, Meier B, et al. Whitethorn/passion flower extract for increase of physical performance in patients with dyspnoea at functional stage NYHA II. Forschende Komplementarmedizin 1994;1:120‐6.
Fischer 1994 {published data only}
    1. Fischer K, Jung F, Koscielny J, Kiesewetter H. Crataegus extract vs. medigoxin. Effects on rheology and microcirculation in 12 healthy volunteers [Crataegus‐extrakt vs. Methyldigoxin. Einfluss auf rheologie und mikrozirkulation bei 12 gesunden probanden Crataegus‐extrakt vs. Methyldigoxin. Einfluss auf rheologie und mikrozirkulation bei 12 gesunden probanden]. Munchener Medizinische Wochenschrift 1994;136(Suppl 1):S35‐S38. [MEDLINE: ; 0341‐3098]
Hellenbrecht 1990 {published data only}
    1. Hellenbrecht D, Saller R, Ruckbeil C, Buhring M. Randomized placebo‐controlled study with crataegus on exercise tests and challenge by catecholamines in healthy subjects. European Journal of Pharmacology 1990;183(2):525‐6. [MEDLINE: ; 0014‐2999]
Rietbrock 2001 {published data only}
    1. Rietbrock N, Hamel M, Hempel B, Mitrovic V, Schmidt T, Wolf GK. Efficacy of a standardized extract of fresh Crataegus berries on exercise tolerance and quality of life in patients with congestive heart failure (NYHA II) [Wirksamkeit eines standardisierten extraktes aus frischen Crataegus‐beeren auf belastungstoleranz und lebensqualitat bei patienten mit herzinsuffizienz (NYHA II).]. Arzneimittel‐Forschung/Drug Research 2001;51(10):793‐798. [MEDLINE: ; 0004‐4172] - PubMed
Schmidt 2000 {published data only}
    1. Schmidt U, Albrecht M, Schmidt S. Effects of an herbal crataegus‐camphor combination on the symptoms of cardiovascular diseases [Effekte einer pflanzlichen Crataegus‐Campher‐Kombination auf die Symptomatik funktioneller Herz‐Kreislauf‐Storungen]. Arzneimittel‐Forschung 2000;50(7):613‐9. [MEDLINE: ; 0004‐4172] - PubMed
Staiger 1987 {published data only}
    1. Staiger J, Kuhn H, Späth J. Zur kardialen Wirksamkeit von low‐dose digitoxin (0.07mg) and crataegus. Medizinische Welt 1987;38:1023‐8.
Tauchert 1994 {published data only}
    1. Tauchert M, Ploch M, Hubner WD. Effectiveness of the hawthorn extract LI 132 compared with the ACE inhibitor captopril. Multicentre double‐blind study with 132 NYHA stage II heart failure patients [Wirksamkeit des weissdorn‐extraktes li 132 im vergleich mit captopril. Multizentrische doppelblindstudie bei 132 patienten mit herzinsuffizienz im stadium ii nach nyha]. Munchener Medizinische Wochenschrift 1994;136(Suppl 1):S27‐S33. [MEDLINE: ; 0341‐3098]
Von 1994 {published data only}
    1. Eiff M, Brunner H, Haegeli A, Kreuter U, Martina B, Meier B, et al. Hawthorn/passion flower extract and improvement in physical exercise capacity of patients with dyspnoea class II of the NYHA functional classification. Acta Therapeutica 1994;20(1‐2):47‐66. [MEDLINE: ; 0378‐0619]
Weikl 1992 {published data only}
    1. Weikl A, Noh HS. Der Einfluss von Crataegus bei globaler Herzin‐suffizienz. Herz Gefässe 1992;12:516‐24.
Weng 1984 {published data only}
    1. Weng WL, Zhang WQ, Liu FZ, Yu XC, Zhang PW, Liu YN, et al. Therapeutic effect of Crataegus pinnatifida on 46 cases of angina pectoris‐‐a double blind study. Journal of Traditional Chinese Medicine = Chung i tsa chih ying wenpan 1984;4(4):293‐4. [MEDLINE: ; 0254‐6272] - PubMed

References to ongoing studies

Holubarsch 2000 {published data only}
    1. Holubarsch CJ, Colucci WS, Meinertz T, Gaus W, Tendera M. Survival and prognosis: investigation of Crataegus extract WS 1442 in congestive heart failure SPICE‐‐rationale, study design and study protocol. European Journal of Heart Failure 2000;2(4):431‐7. [MEDLINE: ; 1388‐9842] - PubMed

Additional references

ACC/AHA 1995
    1. Williams Jr JF, Bristow MR, Fowler MB, Francis GS, Garson Jr A, Gersh BJ, et al. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995;92:2764‐84. - PubMed
Barnes 1998
    1. Barnes J, Mills SY, Abbot NC. Different standards of reporting of ADRs to herbal remedies and conventional OTC medicines: face to face interviews with 515 users of herbal remedies. British Journal of Clinical Pharmacology 1998;45:496‐500. - PMC - PubMed
Blumenthal 1998
    1. Blumenthal M, Busse WR, Goldberg A, et al. The complete German Commission E monographs. Therapeutic guide to herbal medicines. Austin, Texas: American Botanical Council, 1998.
Blumenthal 2000b
    1. Blumenthal M, Goldberg A, Brinckmann J, (eds). Herbal medicine: expanded commission E monographs. Newton, MA: Integrative Medicine Communications, 2000.
Blumenthal 2001
    1. Blumenthal M. Market report. Herbalgram 2001;51:69.
Breevort 1998
    1. Brevoort P. The booming US botanical market. Herbalgram 1998;44:33‐48.
Chang 2002
    1. Chang Q, Zuo Z, Harrison F, Chow MSS. Hawthorn. Journal of Clinical Pharmacology 2002;42:605‐12. - PubMed
Dargie 1994
    1. Dargie HJ, McMurray JJV. Diagnosis and management of heart failure. BMJ 1994;308:321‐8. - PMC - PubMed
Dickersin 1990
    1. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990;263:1385‐9. - PubMed
Doughty 1997
    1. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta‐blocker therapy on mortality in patients with heart failure. European Heart Journal 1997;18:560‐5. - PubMed
Easterbrook 1991
    1. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991;337:867‐72. - PubMed
Egger 1997
    1. Egger M, Zellweger‐Zähner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997;350:326‐9. - PubMed
Egger 1998
    1. Egger M, Davey Smith G. Bias in location and selection of studies. BMJ 1998;316:61‐6. - PMC - PubMed
Eisenberg 1998
    1. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Rompay M, et al. Trends in alternative medicine use in the United States 1990‐1997: results of a national follow‐up survey. JAMA 1998;280:1569‐75. - PubMed
Ernst 1997
    1. Ernst E, Pittler MH. Alternative therapy bias. Nature 1997;385:480. - PubMed
Ernst 2000
    1. Ernst E. Possible interactions between synthetic and herbal medicinal products part 1: a systematic review of the indirect evidence. Perfusion 2000;13:4‐15.
Ernst 2001
    1. Ernst E, Pittler MH, Stevinson C, White AR. The desktop guide to complementary and alternative medicine: an evidence based approach. Edinburgh, UK: Mosby, 2001.
ESC 2001
    1. Swedberg K, Cleland J, Hoes A.W, Gavazzi A, Dargie H, Drexler H, Follath F, et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. European Heart Journal 2001;22:1527‐60. - PubMed
Faris 2006
    1. Faris R, Flather MD, Purcell H, Poole‐Wilson PA, Coats AJS. Diuretics for heart failure. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD003838.pub2] - DOI - PubMed
Fetrow 1999
    1. Fetrow CW, Avila JR. Professional's handbook of complementary and alternative medicines. Sprinhouse, Pa: Springhouse, 1999.
Follmann 1992
    1. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 1992;45:769‐73. - PubMed
Fugh‐Berman 2000
    1. Fugh‐Berman A. Herbs and dietary supplements in the prevention and treatment of cardiovascular disease. Preventive Cardiology 2000;3:24‐32. - PubMed
Herr 2002
    1. Herr SM, Ernst E, Young SL. Herb‐Drug Interaction Handbook. 2nd Edition. Nassau, New York: Church Street Books, 2002.
Higgins 2005
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. www.cochrane.org/resources/handbook/hbook.htm.
Hood 2004
    1. Hood WB, Dans AL, Guyatt GH, Jaeschke R, McMurray J. Digitalis for treatment of congestive heart failure in patients in sinus rhythm. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD002901.pub2] - DOI - PubMed
Joseph 1995
    1. Joseph G, Zhao Y, Klaus W. Pharmacologic action profile of crataegus extract in comparison to epinephrine, amrinone, milrinone and digoxin in the isolated perfused guinea‐pig heart [Pharmakologisches Wirkprofil von Crataegus‐Extrakt im Vergleich zu Epinephrin, Amrinon, Milrinon und Digoxin am isoliert perfundierten Meerschweinchenherzen]. Arzneimittel‐Forschung 1995;45:1261‐5. - PubMed
Kelley 1992
    1. Kelley WN (ed). Textbook of internal medicine. 2nd Edition. Philadelphia; London: JB Lippincott, 1992.
Kernan 1994
    1. Kernan WN, Castellsague J, Perlman GD, Ostfeld A. Incidence of hospitalization for digitalis toxicity among elderly Americans. American Journal of Medicine 1994;96:426‐31. - PubMed
Kiowski 1996
    1. Kiowski W, Sütsch G, Dössegger L. Clinical benefit of angiotensin‐converting enzyme inhibitors in chronic heart failure. Journal of Cardiovascular Pharmacology 1996;27(Suppl 2):S19‐S24. - PubMed
Kraft 2000
    1. Kraft K. Crataegus (common hawthorn) extracts in cardiac failure ‐ are there new promising results and outlooks?. Perfusion 2000;13:495‐8.
Kraft 2001
    1. Kraft K. Therapy of cardio‐vascular diseases using phytopharmaceuticals [Therapie kardiovaskulärer Erkrankungen mit Phytopharmaka]. Biol Med 2001;30:56‐60.
Loew 1997
    1. Loew D. Phytotherapy in heart failure. Phytomedicine 1997;4:267‐71. - PubMed
Lonn 2000
    1. Lonn E, McKelvie R. Drug treatment in heart failure. BMJ 2000;320:1188‐92. - PMC - PubMed
McManus 1998
    1. McManus RJ, Wilson S, Delaney BC, Fitzmaurice DA, Hyde CJ, Tobias RS, et al. Review of the usefulness of contacting other experts when conducting a literature search for systematic reviews. BMJ 1998;317:1562‐3. - PMC - PubMed
Millane 2000
    1. Millane T, Jackson G, Gibbs CR, Lip GYH. ABC of heart failure. Acute and chronic management strategies. BMJ 2000;320:559‐62. - PMC - PubMed
Müller 1999
    1. Müller A, Linke W, Klaus W. Crataegus extract blocks potassium currents in guinea pig ventricular cardiac myocytes. Planta Med 1999;65:335‐9. - PubMed
Narang 1996
    1. Narang R, Swedberg K, Cleland JGF. What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. European Heart Journal 1996;17:120‐34. - PubMed
Nieminen 1999
    1. Nieminen P, Isohanni M. Bias against European journals in medical publication databases. Lancet 1999;353:1592. - PubMed
Pittler 2000
    1. Pittler Mh, Abbot NC, Harkness IF, Ernst E. Location bias in controlled clinical trials of complementary/alternative therapies. Journal of Clinical Epidemiology 2000;53:485‐9. - PubMed
Rotblatt 2002
    1. Rotblatt M, Ziment I. Evidence‐based herbal medicine. Philadelphia, Pennsylvania: Hanley & Belfus, 2002.
Schmidt 1998
    1. Schmidt U, Albrecht M, Podzuweit H. High dosed therapy with crataegus extract in patients suffering from heart failure NYHA stage I and II. Zeitschrift fur Phytotherapie 1998;19:22‐30.
Schmidt 2001
    1. Schmidt K, Pittler MH, Ernst E. Bias in alternative medicine is still rife but is diminishing. BMJ 2001;323:1071. - PMC - PubMed
Schwinger 2000
    1. Schwinger RH, Pietsch M, Frank K, Brixius K. Crataegus special extract WS 1442 increases the force of contraction in human myocardium cAMP‐independently. Journal of Cardiovascular Pharmacology 2000;35:700‐707. - PubMed
Swedberg 1994
    1. Swedberg K. Exercise testing in heart failure. A critical review. Drugs 1994;47(Suppl 4):14‐24. - PubMed
Tankanow 2002
    1. Tankanow R, Tamer HR, Streetman DS. Examination of potential interactions between hawthorn and digoxin in healthy normals. International Scientific Conference on Complementary, Alternative and Integrative Medicine Research; Boston, Massachusetts. 2002.
Tauchert 1999
    1. Tauchert M, Gildor A, Lipinski J. High‐dose crataegus (hawthorn) extract WS 1442 in the treatment of NYHA stage II heart failure [Einsatz des hochdosierten Crataegusextraktes WS 1442 in der Therapie der Herzinsuffizienz Stadium NYHA II]. Herz 1999;24:465‐74. - PubMed
Tsuyuki 2000
    1. Tsuyuki RT, McAlister FA, Teo KK. Beta‐blockers for congestive heart failure: what is the current consensus?. Drugs and Aging 2000;16:1‐7. - PubMed
Von Zerssen 1971
    1. Zerssen DV. The complaints‐list as test [Die Beschwerden‐Liste als Test]. Therapiewoche 1971;21:1908‐20.

References to other published versions of this review

Pittler 2003
    1. Pittler MH, Ernst E. Hawthorn extract for treating chronic heart failure: meta‐analysis of randomized trials. American Journal of Medicine 2003;114:665‐74. - PubMed

LinkOut - more resources